8-K: Schrödinger Reports Strong Q2 2024 Results, Driven by Software Growth and Drug Discovery Milestones

Schrödinger announced a 21% increase in software revenue and significant progress in its drug discovery programs for the second quarter of 2024.

Summary

• Schrödinger reported total revenue of $47.3 million for the second quarter of 2024, a 35% increase compared to $35.2 million in the same period last year.
• Software revenue grew by 21% to $35.4 million, up from $29.4 million in Q2 2023, driven by new and existing customers and multi-year deal renewals.
• Drug discovery revenue saw a substantial increase of 104%, reaching $11.9 million, compared to $5.8 million in the second quarter of 2023, primarily due to milestone revenue from collaboration programs.
• Software gross margin improved to 80%, up from 77% in the prior year's quarter.
• Operating expenses increased to $84.1 million, compared to $74.9 million in Q2 2023, mainly due to higher R&D spending.
• The company reported a net loss of $54.0 million for the quarter, compared to a net income of $4.3 million in the same quarter of 2023, impacted by changes in the fair value of equity investments.
• Non-GAAP net losses were $48.1 million for the quarter and $110.5 million for the first six months of 2024.
• Schrödinger's cash, cash equivalents, restricted cash, and marketable securities totaled approximately $381.5 million as of June 30, 2024, down from $468.8 million at the end of 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with strong revenue growth but a significant net loss. The positive progress in drug development and the Morphic acquisition are counterbalanced by increased operating expenses and a decrease in cash reserves. The updated guidance for software gross margin is also a concern.

Positives

• The company experienced strong growth in both software and drug discovery revenue.
• Software gross margin improved, indicating increased profitability in that segment.
• The predictive toxicology initiative has the potential to enhance drug development and reduce failure rates.
• The company's proprietary therapeutics pipeline is progressing with multiple clinical trials underway.
• The acquisition of Morphic Holding validates Schrödinger's business model and provides a financial benefit through share ownership and royalties.

Negatives

• The company reported a net loss of $54.0 million for the second quarter of 2024, a significant decrease compared to the net income of $4.3 million in the same quarter of 2023.
• Operating expenses increased due to higher R&D spending.
• Cash reserves decreased from $468.8 million at the end of 2023 to $381.5 million as of June 30, 2024.
• The company updated its 2024 full-year guidance for software gross margin to be slightly lower than 2023 and in the range of 2022.

Risks

• The company's financial performance is subject to fluctuations in the value of equity investments.
• The company relies on third-party providers for cloud-based infrastructure.
• Drug development and commercialization are inherently uncertain, with risks associated with clinical trials and regulatory approvals.
• The company's future success depends on its ability to retain and hire key personnel.
• The company's cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023.

Future Outlook

Schrödinger updated its 2024 full-year guidance, expecting software revenue growth between 6% and 13%, drug discovery revenue between $30 million and $35 million, software gross margin slightly lower than 2023 and in the range of 2022, and operating expense growth between 8% and 10%. Cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023. For the third quarter of 2024, software revenue is expected to range from $32 million to $34 million.

Management Comments

• We are very pleased with our results for the second quarter.
• We delivered 21% software revenue growth, and we see many opportunities for customers to increase their scale of adoption of our technology.
• Our recently announced predictive toxicology initiative reflects our commitment to investing in the science underlying our platform to drive future growth.
• Recent clinical and corporate milestones at co-founded companies further validate our platform and underscore the strength of our business model.
• Our proprietary therapeutics pipeline also continues to progress, and we look forward to sharing the initial Phase 1 data from each of our three lead programs next year, starting with SGR-1505 in the first half of 2025.

Industry Context

The announcement reflects the growing trend of using computational platforms and AI in drug discovery and development, with a focus on improving efficiency and reducing costs. The predictive toxicology initiative aligns with the industry's need for safer and more effective drug candidates. The acquisition of Morphic Holding by Lilly highlights the value of companies leveraging computational methods in drug discovery.

Comparison to Industry Standards

• Schrödinger's 21% software revenue growth is strong compared to some of its peers in the computational drug discovery space, although direct comparisons are difficult due to varying business models.
• The 104% increase in drug discovery revenue is notable, indicating successful progression of collaboration programs, which is a key metric for companies in this sector.
• The software gross margin of 80% is competitive with other software companies, but the overall net loss highlights the high R&D costs associated with drug development.
• The Morphic Holding acquisition by Lilly for $3.2 billion is a significant validation of Schrödinger's co-founding model, and is comparable to other large pharmaceutical acquisitions of biotech companies with promising pipelines.
• The clinical trial progress of SGR-1505, SGR-2921, and SGR-3515 is in line with the timelines of other companies developing novel therapeutics, but the success of these trials will be critical for future growth.

Stakeholder Impact

• Shareholders may be concerned about the net loss but encouraged by the revenue growth and pipeline progress.
• Employees may be impacted by the company's focus on R&D and the potential for future growth.
• Customers may benefit from the company's expanded computational platform and drug discovery capabilities.
• Suppliers and creditors may be impacted by the company's financial performance and cash flow.

Next Steps

• Schrödinger will continue to advance its Phase 1 clinical trials for SGR-1505, SGR-2921, and SGR-3515.
• The company will focus on expanding its computational platform for predictive toxicology.
• Schrödinger will continue to develop its proprietary therapeutics pipeline and collaborate with partners.
• The company will host a conference call to discuss its second quarter 2024 financial results.

Key Dates

Keywords

Schrödinger, Software Revenue, Drug Discovery, Computational Platform, Predictive Toxicology, Clinical Trials, SGR-1505, SGR-2921, SGR-3515, Morphic Holding, FDA Fast Track Designation, AI, Bill & Melinda Gates Foundation